Postpartum Depression Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: April 10, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 5.2 billion |
|
Revenue Forecast in 2031 |
US$ 55.14 billion |
|
CAGR |
30% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Drug Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global postpartum depression therapeutics market was valued at US$ 5.2 billion in 2022 and is expected to register a revenue CAGR of 30% to reach US$ 55.14 billion by 2031.
Postpartum Depression Therapeutics Market Fundamentals
Postpartum depression is a type of depression that affects some women after giving birth. It is a mood disorder that can cause sadness, anxiety, and despair, making it difficult for a new mother to care for herself and her baby. Postpartum depression typically occurs within the first few weeks or months after giving birth. However, it can sometimes develop up to a year later. Symptoms may include hopelessness, loss of interest in activities, changes in appetite and sleep patterns, and difficulty concentrating. Postpartum depression therapeutics refer to the various treatments and interventions used to manage the symptoms of postpartum depression, a type of depression that occurs in women after giving birth. Postpartum depression therapeutics aim to alleviate symptoms of depression, anxiety, and other related mental health issues.
Postpartum depression is a common condition affecting women after childbirth. The increasing incidence of postpartum depression is driving demand for effective treatments and contributing to the postpartum depression therapeutics market revenue growth. According to the National Center for Biotechnology Information, postpartum depression occurs in around 6.5% to 20% of women globally. According to the Postpartum Depression Organization, it is estimated that nearly 50% of mothers with postpartum depression are not diagnosed by a health professional.
[46632]
Postpartum Depression Therapeutics Market Dynamics
There is a growing awareness of postpartum depression among healthcare professionals and the general public, leading to increased diagnosis rates. This increased awareness is segmenting postpartum depression therapeutics demand. The availability of various effective treatments for postpartum depression, such as antidepressant medications, is contributing to the market's revenue. This is due to the increasing number of women seeking treatment for their postpartum depression symptoms, thereby driving demand for these treatments.
There is a rise in the demand for antidepressant drugs as these are the most commonly prescribed medications, and this postpartum depression therapeutics market trend is expected to continue during the forecast period. Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, and paroxetine are among the most commonly prescribed drugs for postpartum depression and anxiety. Researchers are exploring genetic testing to identify patients most likely to benefit from certain treatments, increasing the R&D related to personalized medicine for postpartum depression. Governments worldwide are increasingly recognizing the importance of maternal mental health and are implementing initiatives and funding to support postpartum depression research and treatment. This propels the postpartum depression therapeutics market revenue growth as more resources become available to support postpartum depression treatment and research. However, there is still a stigma around mental health that may prevent some women from seeking treatment which is restricting the postpartum depression therapeutics market revenue growth. The development and approval of new depression treatments can be a lengthy and expensive process which is also cramping the postpartum depression therapeutics market revenue growth.
The global postpartum depression therapeutics market outlook is positive as the demand for effective treatments for postpartum depression continues to grow. With increasing awareness of the condition and a greater willingness to seek help for mental health issues, the market is expected to grow during the forecast period. Moreover, the ongoing research and development in the field are expected to lead to the development of the postpartum depression therapeutics industry.
The market for postpartum depression therapeutics includes a range of treatments, including medications such as antidepressants and hormone therapy, psychotherapy, and other non-pharmacological interventions. Some of the key players in the market include Sage Therapeutics, Inc., Pfizer Inc., Novartis AG, and Bausch Health Companies Inc.
However, there are challenges in the postpartum depression therapeutics market, such as the stigma surrounding mental health issues and the high cost of some treatments. In addition, there is still a need for more effective and targeted treatments that can address the specific symptoms and needs of individual patients.
Postpartum Depression Therapeutics Market Ecosystem
The global postpartum depression therapeutics market is analyzed from four perspectives: type, drug type, and region.
Postpartum Depression Therapeutics Market by Type
[789456]
Based on the type, the global postpartum depression therapeutics market is segmented into postpartum anxiety, postpartum blues, postpartum post-traumatic stress disorder, postpartum psychosis, and others.
The anxiety segment accounted for the largest postpartum depression therapeutics market revenue share in 2022 because postpartum anxiety is the most common type of postpartum depression. According to a study published in the journal Acta Clinica Croatica, roughly 75% of women with maternal depression also had signs of postpartum anxiety disorder. Additionally, anxiety symptoms can often co-occur with depression symptoms, making it difficult to differentiate between the two conditions. This has led to an increasing focus on developing treatments that address postpartum anxiety. Additionally, anxiety symptoms often co-occur with depression symptoms, making differentiation difficult. This has led to an increasing focus on developing treatments that address both postpartum anxiety and depression. This can result in a higher demand for treatment options, leading to a larger size for postpartum anxiety therapeutics. There is a rise in the number of therapeutics for postpartum anxiety, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT). This has contributed to the dominance of the postpartum anxiety segment in the postpartum depression therapeutics market.
The postpartum blues segment accounted for a prominent revenue share of the postpartum depression therapeutics market because it is one of the most common forms of postpartum mood disorder, affecting a large proportion of new mothers. However, postpartum blues are typically self-limiting; most women recover without intervention within a few weeks. Some women with postpartum blues may develop more severe forms of postpartum depression, such as major postpartum depression or postpartum psychosis, which require more intensive treatment. Therefore, early intervention with postpartum blues may help prevent the development of more severe forms of postpartum depression, which may drive demand for treatment options. There is an increasing awareness among healthcare professionals and the public about the importance of identifying and treating postpartum mood disorders, including postpartum blues. This has led to more screening and diagnosis of postpartum blues and a greater demand for treatment options.
Postpartum Depression Therapeutics Market by Drug Type
Based on drug types, the global postpartum depression therapeutics market is segmented into antidepressants, antipsychotics, and others.
With the largest revenue share antidepressants drugs segment dominated the postpartum depression therapeutics market in 2022. Antidepressants are currently the most effective and widely used pharmacological treatment for postpartum depression. Antidepressants work by increasing the availability of certain neurotransmitters in the brain, such as serotonin and norepinephrine, which are believed to be deficient in people with depression. This helps to alleviate the symptoms of depression, including those associated with postpartum depression. SSRIs are the most commonly prescribed antidepressants for postpartum depression, as they are generally well-tolerated and have fewer side effects than other antidepressants. Antidepressants are often prescribed for postpartum depression because they can be effective in a relatively short period, typically within 2-4 weeks. This can be important for new mothers who need to feel better quickly in order to care for their newborns.
The antipsychotic drugs segment also accounted for a significant revenue share of the postpartum depression therapeutics market. Antipsychotic drugs are another key postpartum psychosis treatment, and they can be effective in reducing the severity of symptoms. Antipsychotics work by blocking the activity of dopamine receptors in the brain. They are also sometimes used with antidepressants for the treatment of postpartum depression, particularly in cases where depression is accompanied by severe anxiety or agitation.
Postpartum Depression Therapeutics Market by Region
Geographically, the global postpartum depression therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
There is a rise in the prevalence of postpartum depression in North America. The Pregnancy Risk Assessment Monitoring System (PRAMS), a CDC research, shows that about 1 in 8 women with a recent live birth experience symptoms of postpartum depression. The rising incidence is driving demand for postpartum depression therapeutics as more women seek treatment for this condition. There is growing awareness among healthcare professionals and the public about the importance of identifying and treating postpartum depression, which has led to more screening and diagnosis of the condition. This increased awareness is driving demand for postpartum depression therapeutics in North America. There are supportive healthcare policies in place in North America, such as the Affordable Care Act in the United States, which mandate insurance coverage for mental health services, including depression treatment. There is a growing focus on maternal mental health in North America, with healthcare providers and policymakers recognizing the importance of addressing postpartum depression and related conditions to support the health and well-being of mothers and their children. This focus drives the postpartum depression therapeutics demand as more resources are allocated to addressing this important public health issue.
Competitive Landscape of the Global Postpartum Depression Therapeutics Market
The prominent players operating in the global postpartum depression therapeutics market are:
Strategic Developments in Postpartum Depression Therapeutics Market
The expected size of the global postpartum depression therapeutics market in 2031 is US$ 55.14 billion.
Based on region, North America has the largest market revenue share, followed by Europe, and Asia Pacific is expected to be the fastest-growing region during the forecast period.
The prominent players operating in the global postpartum depression therapeutics market are Sage Therapeutics, Inc., Pfizer Inc., Novartis AG, Bausch Health Companies Inc., GlaxoSmithKline plc, and Mylan N.V.
During the forecast period, the revenue CAGR of the global postpartum depression therapeutics market is expected to be 30%.
The antidepressants segment dominates the global postpartum depression therapeutics market.
*Insights on financial performance are subject to the availability of information in the public domain